RxDoctor Payments Data

Franchesca Fiorito-Torres, MD

Neurology · San Juan, PRNPI 1225340847

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $350,294 of the $452,551 with a category attached, or 77.4%. 20 manufacturers reported payments, led by AbbVie at 46.2% of the total. Reporting peaked in 2021 at $114,990 and has fallen 73.5% since, to $30,436 in 2025. Among neurology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$452,551in general payments, 2019–2025

Across 610 payments — averaging $741.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$209K
  • Lilly USA, LLC$68K
  • Biohaven Pharmaceutical Holding Company Ltd.$62K
  • Biohaven Pharmaceuticals, Inc.$55K
  • Teva Pharmaceuticals USA, Inc.$19K
  • Amgen$11K
  • plus $28K from 14 others
$36,843in research payments, 2019–2025

Across 9 payments — averaging $4093.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$37K

What the payments were for

  • Consulting fees$52,90012%
  • Speaking & faculty fees$350,29477%
  • Grants$440%
  • Travel & lodging$33,1887%
  • Food & beverage$15,9664%
  • Education$1590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$452,551 in reported general payments places this provider in the 95th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,024
Medicare patients
13
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm384$278,929
Nurtec OdtRimegepant Sulfate228$271,671
UbrelvyUbrogepant197$242,009
Ajovy AutoinjectorFremanezumab-Vfrm209$155,407
QuliptaAtogepant118$130,867
Aimovig AutoinjectorErenumab-Aooe144$109,402
ReyvowLasmiditan Succinate71$61,689
BotoxOnabotulinumtoxina23$28,940
OzempicSemaglutide12$11,717
Emgality SyringeGalcanezumab-Gnlm14$10,010
Eletriptan HbrEletriptan Hydrobromide93$8,421
RizatriptanRizatriptan Benzoate160$4,578
Diclofenac Potassium94$4,205
Gabapentin270$3,341
Tizanidine Hcl233$2,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$209,034$401,816338 claims
PfizerNurtec Odt$1,000$271,671228 claims
Lilly USA, LLCReyvow$68,219$61,68971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 neurology providers in Puerto Rico.

Other neurology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →